Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Next Previous
X
Search
Trial Profile

A Phase IB Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mosunetuzumab (Primary) ; Tocilizumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Roche

    • Most Recent Events

    • 04 Dec 2023 Study design is changed from single-group assignment to parallel. Number of treatment arms increased from 1 to 3 by the addition of Arms B and C, where mosunetuzumab in combination with venetoclax is used in the regimen of arm C. Timeline for primary end-point for Arm-C is added as 24 months.
    • 04 Dec 2023 Planned number of patients changed from 56 to 137.
    • 04 Dec 2023 Planned End Date changed from 31 Jul 2027 to 8 Oct 2029.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top